Cyclosporine Articles
Ulcerative colitis drug market will nearly double to $2.1 billion in 2018 in top seven markets
15 February 2010
UK’s MHRA advice on immunosuppressant ciclosporin highlights risk of automatic substitution of generic drugs
2 February 2010
Sanofi-Aventis’ latest shopping spree includes France’s Fovea and deal with Merrimack
1 October 2009
US FDA guidance for old antibiotic patents
15 December 2008
APT Pharma secures $32.3M financing
6 October 2008
Barr shares fall 15% on disappointing 1st qtr
19 May 2008
US fast-track for Lux Biosciences' LX201
4 February 2008
Myfortic cuts GI effects in transplant recipients
14 January 2008
New Rapamune dosing guide OKed by FDA
12 February 2007
Two orphan designations for Lux Biosciences
22 January 2007
German OK for Isotechnika Ph III psoriasis trial
9 October 2006
Tenby Pharma emerges with $25M financing
25 September 2006
Novartis' Neoral performs well in study
31 July 2006
Positive kidney transplant data for Atellas' Prograf
26 July 2006
Prograf gets FDA OK for heart transplant care
10 April 2006
Allergan reports strong 4th-qtr results
13 February 2006
CMHP issues positive opinion to S-P/Centocor's Remicade edging; closer to approval in the EU
6 February 2006
Novartis sees strong performance with record results in 2005
30 January 2006
FDA knocks back Novartis' Certican
5 December 2005
Stock Commentary - New York
25 July 2005
FDA requests extra trial for Chiron's Pulminiq
25 July 2005
US FDA: Chiron's Pulminiq needs no more testing
13 June 2005
US court upholds FDA classification of Allergan's Restasis
31 January 2005
Priority review for Chiron's Pulminiq
10 January 2005
Raptiva launched in UK for psoriasis
8 November 2004
Chiron submits NDA for Pulminiq
25 October 2004
Serono's Raptiva Oked for psoriasis in EU
4 October 2004
Novartis' Myfortic launched in UK
20 September 2004
ALERT study confirms Lescol safety
13 September 2004
Novartis' Certican delayed in USA
6 September 2004
Novartis' Certican launched in Germany
29 March 2004
Novartis' Myfortic cleared by FDA
8 March 2004
Healthy interim ressults for S Africa's Aspen
1 March 2004
Stock Commentary - New York
16 February 2004
Novartis' Myfortic completes EU's MRP
16 February 2004
Novartis' Certican cleared in EU
15 December 2003
Allergan and Inspire sign deal for Elestat
15 December 2003
Novartis' Certican faces delay in USA
27 October 2003
Novartis' sales on track in third quarter; profits rise 7% as Diovan, Gleevec deliver
27 October 2003
Neoral improves donor kidneys' survival
16 June 2003
Promising Phase IIa data for ISA247
16 June 2003
Profits flat at Novartis despite sales growth
21 April 2003
Cyclosporine aerosol of use in lung transplants?
21 April 2003
Rapamune gets new indication from FDA
21 April 2003
Novartis' Certican tops azathioprine
21 April 2003
SangStat reports first profitable year
17 February 2003
SangStat files ciclosporin capsules in Europe
27 January 2003
Restasis approval boosts Allergan
6 January 2003
Analysts see threat to Novartis' Lotrel
6 January 2003
IVAX wins generic approvals in Poland
8 July 2002
Drugmakers warn over German generics move
17 June 2002
Isotechnika, Roche to delay arthritis trial
20 May 2002
CellCept switch boosts renal function
6 May 2002
New data on Novartis transplant drugs
6 May 2002
PDL yo-yos as Zenapax trial misses endpoint
1 April 2002
Double-digit turnover growth for Novartis in 2001
11 February 2002
FDA panel votes against new Rapamune use
4 February 2002
New labeling for Wyeth's Rapamune?
7 January 2002
PDL to test Zenapax in asthma patients
28 November 2001
Novartis files Myfortic in Europe
1 November 2001
Double-digit turnover growth for Novartis
11 October 2001
Novartis' six-month 2001 net income jumps 10%, sales up 11%
16 August 2001
Further promising preclinical data for Oncolytics' Reolysin
10 August 2001
Rapamune transplant drug approved in Canada
6 June 2001
EU court to rule on SangStat's SangCya
18 April 2001
New drugs "driving French budget rise"
5 February 2001
Novartis looking to get bigger
31 January 2001
Merck & Co gets US approval for new antifungal agent Cancidas
30 January 2001
Wyeth's Rapamune gains CPMP backing
12 December 2000
Novartis R&D day updates prospects for key pipeline drugs
7 December 2000
Prograf driving Fujisawa sales
13 November 2000
Sangstat acquires new cyclosporine capsule
12 October 2000
SangStat wins Thymoglobulin OK in Italy
4 September 2000
Novartis gets CPMP OK for pediatric Simulect
23 August 2000
Novartis puts in solid 1st-half performance
21 August 2000
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- AstraZeneca plans to move three cancer drug candidates into Ph III
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- Merck Serono Ph III trial of L-BLP25 fails endpoint in NSCLC
